510(k) Report

510(k) · Cleared

Cleared

Architect Stat CK-MB Immunoassay

K041596510(k) TraditionalCleared Jul 21, 200437-day reviewClass II21 CFR 862.1215

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Fisher Diagnostics · JHX Fluorometric Method, Cpk Or Isoenzymes

Cleared on Jul 21, 2004 as substantially equivalent to K935924 (Abbott Laboratories, 1994) after a 37-day review. Its family tree reaches back 1 generation to 1994.

Decided
Jul 21, 2004
Review
37 days
Class
Class II
Product code
JHX
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K935924 (1994). No later device cites it as a predicate yet.

K935924 · Axsym CK-MB · Abbott Laboratories · 19941990199520002005
K935924 · Axsym CK-MB · Abbott Laboratories · 19940
  1. Root · 1 generation backK935924 Axsym CK-MBAbbott Laboratories · 1994
  2. This deviceK041596 Architect Stat CK-MB ImmunoassayFisher Diagnostics · 2004
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K935924Axsym CK-MBAbbott Laboratories1994—
0 (this device)K041596Architect Stat CK-MB ImmunoassayFisher Diagnostics2004—
FIG. 1 — Lineage of K041596, 1994–2004Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JHX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new JHX device

  1. #1 K234005 Access CK-MBscore 7.2 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K935924Axsym CK-MB
Summary page 1
…lation: 21 CFR 862.1215 FDA Panel: Clinical Chemistry Product Code: bM4 11 Identification of Predicate Device: Abbott AxSYM® CK-MB Assay (K935924) Intended Use of the Device: ARCHITECT STAT OK-MB is a Chemiluminescent Microparticle Immunoassay (OMIA) for t…
Abbott Laboratories1994—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All JHX devices

JHX Fluorometric Method, Cpk Or Isoenzymes: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · JHX

1in 2024

2009: 12012: 12017: 12022: 12024: 1
2007high 1 (2009) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JHX

Too few JHX 510(k)s in any year since 2007 to give a median.

Recalls per year · JHX

2in 2015

2008: 12009: 12012: 42015: 2
2007high 4 (2012) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JHX

1in 2025

2007: 22008: 62009: 402010: 272011: 42012: 182013: 82014: 172015: 82016: 102017: 32018: 162019: 72020: 32021: 102022: 22023: 22024: 22025: 1
2007high 40 (2009) · low 1 (2025)2025

MAUDE reports naming product code JHX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—02
20080—16
20091—140
20100—027
20110—04
20121—418
20130—08
20140—017
20150—28
20160—010
20171—03
20180—016
20190—07
20200—03
20210—010
20221—02
20230—02
20241—02
20250—01
20260—0—

What is it indicated for?

ARCHITECT STATCK-MB is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of CK-MB in human serum and plasma on the ARCHITECT i System with STAT capability. CK-MB values are used to assist in the diagnosis of myocardial infarction (MI).

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K041596: Architect Stat CK-MB Immunoassay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K041596

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026